JADPRO | Volume 10, Supplement 3 (May/Jun 2019)

CAR T-Cell Therapy for Large B-Cell Lymphoma

Practical information for the advanced practitioner on a revolutionary cancer treatment

This supplement to JADPRO, developed in partnership with Nexus Global Group Science LLC, aims to provide practical information to advanced practitioners on a number of considerations when implementing CAR T-cell therapy. It is sponsored by Kite, a Gilead Company.

Editorial

CAR T-Cell Therapy for Large B-Cell Lymphoma

Abstract Chimeric antigen receptor (CAR) T-cell therapy represents an exciting innovation in the treatment of cancer. With the approval of two revolutionary anti-CD19 CAR T-cell therapies (axicabtagene ciloleucel [Yescarta] and tisagenl...

May 21, 2019

Review Article

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma

Abstract Chimeric antigen receptor (CAR) T-cell therapies represent a new paradigm in targeted cancer therapy. T cells play a key role in immune surveillance, but tumors have developed multiple mechanisms for evading that surveillance. ...

May 21, 2019

Review Article

CAR T-Cell Therapy: Adverse Events and Management

Abstract Chimeric antigen receptor (CAR) T-cell therapy is an exciting innovation in the treatment of cancer. However, CAR T-cell therapies have been associated with unique adverse events (AEs), including cytokine release syndrome (CRS)...

May 21, 2019

Review Article

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Abstract Two anti-CD19 chimeric antigen receptor (CAR) T-cell therapies are approved for adults with relapsed or refractory large B-cell lymphoma after more than two lines of therapy. Although CAR T-cell therapy has demonstrated signifi...

May 21, 2019

How Do We Achieve Value-Based, Patient-Centered Care?

Beth Faiman

September 16, 2024

Is it Cellulitis Again? Erythema Concerning for Infection in Children With High-Risk Solid Tumors Who Have a Gastrostomy Tube

Kristen L. Dalton, MSN, RN, CPNP-AC, CPHON, Meredith R. Johnson, MSN, RN, CRNP-AC

September 16, 2024

Carcinoid Heart Disease

Nicole Kuhnly, MS, ACNPC-AG, Jessica Shank Coviello, DNP, APRN, ANP-BC, Catherine A. Kobza, MSN, AGACNP-BC, Et al.

September 16, 2024

Table of Contents Archive

Volume 10, Supplement 3 (May/Jun 2019)

CAR T-Cell Therapy for Large B-Cell Lymphoma

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma

CAR T-Cell Therapy: Adverse Events and Management

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Current Issue

How Do We Achieve Value-Based, Patient-Centered Care?

Is it Cellulitis Again? Erythema Concerning for Infection in Children With High-Risk Solid Tumors Who Have a Gastrostomy Tube

Carcinoid Heart Disease

Recent Issues

Issues

Sections

Solid Tumors

Hematologic Malignancies

Issues in Oncology

Supportive Care

Developmental Therapeutics

Live Events

Webinars

Educational Resources

Volume 10, Supplement 3 (May/Jun 2019)

CAR T-Cell Therapy for Large B-Cell Lymphoma

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma

CAR T-Cell Therapy: Adverse Events and Management

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Current Issue

How Do We Achieve Value-Based, Patient-Centered Care?

Is it Cellulitis Again? Erythema Concerning for Infection in Children With High-Risk Solid Tumors Who Have a Gastrostomy Tube

Carcinoid Heart Disease

Recent Issues